|Bid||328.80 x 900|
|Ask||329.11 x 1000|
|Day's Range||324.66 - 329.23|
|52 Week Range||226.02 - 373.90|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||56.67|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||1.36 (0.43%)|
|1y Target Est||400.45|
WAYNE, Pa., Oct. 17, 2019 -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the third quarter 2019 will be released before market open on.
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Teleflex Incorporated (NYSE:TFX) saw significant share price movement during recent months on the NYSE, rising to...
Teleflex Inc. announced Monday a voluntary recall of its Babi.Plus water pressure relief manifold following a notice received from manufacturer GaleMed Corp. after reports that the bubble continuous positive airway pressure (BCPAP) pressure system would not hold pressure. The company said the recalled products were distributed from October 2018 to May 2019. GaleMed said it received two reports of device malfunction but no reports of injuries. The Food and Drug Administration is classified the recall as a Class 1 recall, which is defined as "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." Teleflex's stock, which was still inactive in premarket trading, has rallied 27.7% year to date, while the S&P 500 has gained 17.8%.
Teleflex Incorporated (TFX), announced a recall June 14th, 2019 of certain lots of the GaleMed (third party manufacturer) Babi.Plus® 12.5 cm H2O Pressure Relief Manifold. Teleflex receives the product from the manufacturer GaleMed Corporation and is one of its distributors for this product within the United States.
Teleflex Incorporated (TFX), a leading global provider of medical technologies, today announced the tenth anniversary of its industry-leading GuideLiner® Catheter. Released in November 2009, the GuideLiner® Catheter revolutionized the concept of guide extension in the medical device industry. Since that time, the company has sold more than 1 million GuideLiner® Catheters—from three product generations—across 62 countries, including more than 550,000 units in North America alone.
Teleflex Incorporated (TFX) today announced the publication of an article showcasing the effectiveness and overall benefits of the minimally invasive UroLift® System treatment for patients with benign prostatic hyperplasia (BPH). The article, DeMISTifying less-invasive solutions for BPH, reviews the objectives of using minimally invasive surgical technologies (MIST) to treat BPH, and recommends useful metrics to measure the success of these treatments, including the UroLift System. The article, published in Urology Times, is authored by Steven Kaplan, M.D., professor of Urology, Icahn School of Medicine at Mount Sinai and director of the Men’s Health Program at Mount Sinai Health System, New York.
WAYNE, Pa., Sept. 13, 2019 -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will focus on its Arrow® EZ-IO® Intraosseous Access System.
Executive Vice President & CFO of Teleflex Inc (30-Year Financial, Insider Trades) Thomas E Powell (insider trades) sold 7,500 shares of TFX on 09/06/2019 at an average price of $355.52 a share. Continue reading...
WAYNE, Pa., Aug. 30, 2019 -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will showcase its Peripheral Intervention product portfolio.
WAYNE, Pa., Aug. 28, 2019 -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 17th Annual Global Healthcare.
How far off is Teleflex Incorporated (NYSE:TFX) from its intrinsic value? Using the most recent financial data, we'll...
WAYNE, Pa., Aug. 21, 2019 -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo Securities 2019 Healthcare Conference at.
Teleflex Incorporated (TFX) today announced the UroLift® System, a proven, minimally invasive treatment for patients with benign prostatic hyperplasia (BPH), won the 2019 James & Wells Medical Technology Association of New Zealand (MTANZ) Innovation Award at the Health Tech Week Gala on July 2. The MTANZ Innovation Award recognizes products that significantly contribute to improving patient outcomes by enhancing their quality of life, as well as exhibiting technical excellence and innovation across the entire medical device sector. Recipients for the MTANZ Innovation Award are determined by a judging panel consisting of distinguished industry leaders and clinicians.
Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 2.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
WAYNE, Pa., Aug. 01, 2019 -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per.
Second Quarter Revenues from Continuing Operations of $652.5 million, up 7% versus Prior Year Period; up 9.6% on a Constant Currency Basis Second Quarter GAAP Diluted EPS from.